Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

Doxazosin mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for doxazosin mesylate and what is the scope of doxazosin mesylate freedom to operate?

Doxazosin mesylate
is the generic ingredient in three branded drugs marketed by Mylan, Nesher Pharms, Accord Hlthcare, Watson Labs Inc, Idt Australia Ltd, Teva, Sandoz, Pliva, Ivax Sub Teva Pharms, Dava Pharms Inc, Genpharm, Pfizer, Actavis Elizabeth, and Apotex, and is included in sixteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for doxazosin mesylate. Thirty-five suppliers are listed for this compound.

Summary for Generic Name: doxazosin mesylate

Tradenames:3
Patents:1
Applicants:14
NDAs:16
Drug Master File Entries: see list13
Suppliers / Packagers: see list35
Bulk Api Vendors: see list59
Clinical Trials: see list191
Patent Applications: see list2,490
Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:doxazosin mesylate at DailyMed

Pharmacology for Ingredient: doxazosin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs Inc
DOXAZOSIN MESYLATE
doxazosin mesylate
TABLET;ORAL075426-001Oct 18, 2000DISCNNoNo► Subscribe► Subscribe
Nesher Pharms
DOXAZOSIN MESYLATE
doxazosin mesylate
TABLET;ORAL075609-001Oct 18, 2000DISCNNoNo► Subscribe► Subscribe
Pliva
DOXAZOSIN MESYLATE
doxazosin mesylate
TABLET;ORAL075750-001Jun 8, 2001ABRXNoNo► Subscribe► Subscribe
Teva
DOXAZOSIN MESYLATE
doxazosin mesylate
TABLET;ORAL075353-002Jan 12, 2001DISCNNoNo► Subscribe► Subscribe
Dava Pharms Inc
DOXAZOSIN MESYLATE
doxazosin mesylate
TABLET;ORAL076161-004Jun 10, 2004ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot